// App-Quantinova.ai

593 : Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.

Researchers

Presenter

  • Carlos H. Barrios

Principal Investigators

  • David Cella

  • Miguel Martin

  • Wolfgang Eiermann

  • Howard A. Burris

  • Young-Hyuck Im

  • Pier Franco Conte

  • Masakazu Toi

  • Tadeusz Pienkowski

  • Xavier B. Pivot

  • Benjamin Beckermann

  • Sven Franz Stanzel

  • Jennifer Petersen

  • Paul Anthony Ellis

Medical Centers

  • PUCRS School of Medicine, Porto Alegre, Brazil

  • Feinberg School of Medicine, Northwestern University, Chicago, IL

  • Instituto de Investigacion Sanitaria Gregorio Maranon, Universidad Complutense, Madrid, Spain

  • Interdisciplinary Oncology Center, Munich, Germany

  • Sarah Cannon Research Institute, Nashville, TN

  • University of Padova and Istituto Oncologico Veneto IOV IRCCS, Padova, Italy

  • Graduate School of Medicine Kyoto University, Kyoto, Japan

  • Postgraduate Medical Center, Warsaw, Poland

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Genentech, Inc., South San Francisico, CA

  • Guys Hospital and Sarah Cannon Research Institute, London, United Kingdom

Locations

  • Brazil

  • Japan

  • Italy

  • Poland

  • Spain

  • Germany

  • Switzerland

  • United Kingdom

  • United States

  • France

Companies

  • F. Hoffmann-La Roche

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab emtansine

  • Pertuzumab

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01120184

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved